[ad_1] BERWYN, Pa., November 12, 2020 (GLOBE NEWSWIRE) – Annovis Bio Inc. (NYSE American: ANVS), a clinical stage pharmaceutical platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced today that it has successfully completed the dog cohort of a chronic toxicology study on its lead …
Read More »Annovis Bio Reports Positive Final Phase Results of NIH $ 1.9 Million Funded Chronic Toxicology Study for Its Leading Compound for Alzheimer’s and Parkinson’s Disease Treatment
